Sugi Predict

Sugi Predict / Compounds / SCHEMBL518157

SCHEMBL518157

SCHEMBL518157

CC(C)(C)OC(=O)N1CCC(=O)C(F)(F)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ NR1H2 P55055 2/20 0.41
▸ DDB1 Q16531 3/20 0.40
▸ CRBN Q96SW2 3/20 0.40
▸ CYP11B2 P19099 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ PDK4 Q16654 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ GRM5 P41594 1/20 0.37
▸ EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL26621617 0.98 USP2 (0.41) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL30075744 0.86 NR1H2 (0.43) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL15749495 0.86 NR1H2 (0.43) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL31510778 0.86 USP2 (0.45) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL30164921 0.85 USP2 (0.38) USP2SMN1; SMN2ESR2CYP11B2USP30
SCHEMBL29143178 0.84 NR1H2 (0.44) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL20400529 0.84 GRM5 (0.40) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL29440339 0.83 USP2 (0.41) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL29286890 0.83 USP2 (0.41) USP2SMN1; SMN2ESR2NR1H2DDB1
SCHEMBL517374 0.83 NR1H2 (0.46) USP2SMN1; SMN2ESR2NR1H2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4398904-A1 SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 Therapeutics, Inc. (US) 2024-07-17 — — EP claimed
EP-4353715-A1 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) 2024-04-17 — — EP claimed
CN-117720516-A Advantageous crystalline forms of selective BRD9 degrading agents C4医药公司 2024-03-19 — — CN claimed
WO-2024016783-A1 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR 威尚（上海）生物医药有限公司 2024-01-25 — — WO claimed
WO-2023039208-A1 SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-16 — — WO claimed
CN-115260153-A 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof 威尚（上海）生物医药有限公司 2022-11-01 — — CN claimed
US-20260146050-A1 KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-05-28 — — US disclosed
CN-122079983-A FGFR3 inhibitor compounds — 2026-05-26 — — CN disclosed
CN-122079985-A FGFR3 inhibitor compounds — 2026-05-26 — — CN disclosed
CN-122079984-A FGFR3 inhibitor compounds — 2026-05-26 — — CN disclosed
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 — — EP disclosed
US-20130203987-A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME RIGEL PHARMACEUTICALS, INC. (US) 2013-08-08 — — US disclosed
EP-2598483-A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME Rigel Pharmaceuticals, Inc. (US) 2013-06-05 — — EP disclosed
US-20120028954-A1 Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 — — US disclosed
US-20120028954-A1 Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 — — US disclosed
WO-2012016217-A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 — — WO disclosed
US-20120028954-A1 Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 — — US disclosed
WO-2012016217-A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME RIGEL PHARMACEUTICALS, INC. (US) 2012-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 USP2 1713/4885SMN1; SMN2 1897/4885ESR2 743/4885
US-20120028954-A1 Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same AK2, PC, PRKAG2 USP2 2973/4885SMN1; SMN2 2195/4885ESR2 478/4885
US-20260146050-A1 KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES KRAS, NRAS, HRAS USP2 1008/4885SMN1; SMN2 4075/4885ESR2 425/4885
US-20130203987-A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME PRKAG1, PRKAG2, PRKAB1 USP2 2548/4885SMN1; SMN2 2965/4885ESR2 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.